CVT begins second regadenoson study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CV Therapeutics has initiated a second cardiac perfusion imaging trial of its pharmacologic stress agent regadenoson (CVT-3146), the firm announces April 26. CVT and partner Fujisawa plan to submit an NDA "as quickly as possible." CVT is highlighting a potential safety benefit via regadenoson's selectivity for the A2A-adenosine receptor, responsible for coronary vasodilation. The first Phase III trial started in October 2003...